Vyndamax (Tafamidis): The 2028-2035 Generic Opportunity Window

Pfizer's blockbuster oral transthyretin (TTR) kinetic stabilizer Vyndamax (tafamidis 61 mg oral capsules, NDA 212161) generated $3.32 billion in full-year 2023 global revenues, surging 56% to reach $4.5 billion in full-year 2024, with U.S. annual net sales surpassing $2.5 billion. Indicated for the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adult patients, Vyndamax maintains a 100% brand-only market in the United States today, with zero generic versions commercially approved or selling. Core composition-of-matter and substance patent US 7,214,695 expires in December 2028 following an interim Patent Term Extension granted under 35 U.S.C. 156. Secondary crystalline solid Form 1 polymorph patent US 9,770,441 extends Orange Book protection through August 31, 2035. In April 2026, Pfizer finalized Hatch-Waxman Paragraph IV patent litigation settlement agreements with leading generic manufacturers--including Indian pharmaceutical leader Cipla Limited, alongside Hikma Pharmaceuticals and Dexcel Pharma--authorizing generic market entry on June 1, 2031 (or earlier under standard acceleration triggers), defining the critical 2028-2035 commercial transition window.